Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company based in Bethesda, MD, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' chairman and chief executive officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding chief executive officer and advisor, international business development.

In January 2006, Sucampo received marketing approval from the U.S. Food and Drug Administration for its first product, AMITIZAŽ (lubiprostone) (24 mcg).

 

May 2, 2012
Sucampo Announces First Quarter 2012 Financial Results and Operating Highlights Teleconference and Webcast

Apr 27, 2012
Sucampo Pharmaceuticals Provides Update on Anticipated Arbitration Decision Date

Apr 18, 2012
Sucampo and Clinigen Announce Named Patient Program for European Union, Iceland and Norway to Provide Access to AMITIZA(R) (lubiprostone) for Chronic Idiopathic Constipation Patients